APA (7th ed.) Citation

Haosheng Zheng, Xianyu Qin, Yuzhen Zheng, Xingping Yang, Jian Tan, Weijie Cai, . . . Hongying Liao. (2024). Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: An updated systematic review and meta-analysis. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Haosheng Zheng, Xianyu Qin, Yuzhen Zheng, Xingping Yang, Jian Tan, Weijie Cai, Shiyun He, and Hongying Liao. Addition of Bevacizumab to EGFR Tyrosine Kinase Inhibitors in Advanced NSCLC: An Updated Systematic Review and Meta-analysis. Frontiers Media S.A., 2024.

MLA (9th ed.) Citation

Haosheng Zheng, et al. Addition of Bevacizumab to EGFR Tyrosine Kinase Inhibitors in Advanced NSCLC: An Updated Systematic Review and Meta-analysis. Frontiers Media S.A., 2024.